Meeting
2021 Genitourinary Cancers Symposium
The potential role of frailty in modifying quality-of-life related outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel, abiraterone, enzalutamine, and radium 223.
Authors
Seungyeon Kim
University of Toronto, Toronto, ON, Canada
Seungyeon Kim , Henriette Breunis , Narhari Timilshina , Helen Yang , Shabbir M.H. Alibhai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 63)
DOI
10.1200/JCO.2021.39.6_suppl.63
Abstract #
63
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Impact of treatment and frailty on elder-relevant physical function outcomes in older adults with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Helen Yang
Poster
2013 ASCO Annual Meeting
Effect of abiraterone acetate (AA) on patient-reported pain in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: Results of longitudinal sensitivity analyses.
First Author: Yanni Hao
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.
First Author: Emily Nash Smyth
Poster
2024 ASCO Genitourinary Cancers Symposium
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi